NASDAQ · NTRA
Healthcare · Medical - Diagnostics & Research
$414.30
Down-$21.70 (-4.98%)
Updated Nov 1, 2026, 3:01 PM
SID Score
7.0/10
Composite research score
Smart Money
62/100
Neutral
Price performance · NTRA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NTRA closed at $414.30 after 20 trading sessions, down 2.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $425.55 | $431.2603 | $408.3245 | $414.30 | 2.43M |
| Oct 29, 2026 | $422.53 | $436.19 | $420.15 | $436.00 | 1.33M |
| Oct 28, 2026 | $410.29 | $432.835 | $409.50 | $424.42 | 1.55M |
| Oct 27, 2026 | $402.795 | $415.00 | $401.00 | $410.82 | 1.71M |
| Oct 26, 2026 | $404.71 | $407.88 | $400.00 | $404.90 | 1.43M |
| Oct 23, 2026 | $399.945 | $408.28 | $395.3289 | $403.95 | 1.1M |
| Oct 22, 2026 | $408.47 | $416.00 | $383.76 | $401.37 | 1.61M |
| Oct 21, 2026 | $404.84 | $420.1499 | $404.84 | $413.38 | 1.29M |
| Oct 20, 2026 | $400.01 | $410.28 | $396.09 | $405.92 | 981.42K |
| Oct 19, 2026 | $401.47 | $408.205 | $397.2005 | $399.42 | 1.33M |
| Oct 16, 2026 | $405.76 | $410.6299 | $387.26 | $393.44 | 1.58M |
| Oct 15, 2026 | $389.88 | $408.82 | $384.23 | $404.79 | 1.21M |
| Oct 14, 2026 | $394.40 | $405.11 | $391.28 | $394.75 | 1.05M |
| Oct 13, 2026 | $396.98 | $397.53 | $383.01 | $395.655 | 1.14M |
| Oct 12, 2026 | $401.96 | $402.40 | $387.74 | $397.77 | 935.14K |
| Oct 9, 2026 | $392.90 | $407.06 | $391.51 | $400.71 | 1.01M |
| Oct 8, 2026 | $387.59 | $392.955 | $380.39 | $390.79 | 2.44M |
| Oct 7, 2026 | $393.02 | $401.09 | $383.45 | $395.56 | 2.82M |
| Oct 6, 2026 | $429.01 | $437.4083 | $394.77 | $400.65 | 2.5M |
| Oct 5, 2026 | $410.32 | $427.18 | $405.24 | $425.64 | 2.02M |
The latest Smart Investors Daily articles mentioning NTRA.
Company
Market Activity
Research & News
NTRA research
Company profile and research snapshot.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Buy | — |
| Oct 19, 2026 | Canaccord Genuity | Buy | — |
| Oct 14, 2026 | JP Morgan | Overweight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Key TakeawaysCareDx shares jumped 20% after third-quarter revenue rose 39% to $139 million and the company raised its 2026 revenue guidance to $520 million to $530 million. About $15 million of the quarter’s revenue came from tests run in earlier periods, so the raised guidance tells you more about the business than the beat does.
Yahoo · Oct 30, 2026
Numerous stock market leaders have delivered big gains from the ascending base chart pattern throughout market history.
Yahoo · Oct 29, 2026
CareDx (CDNA) delivered earnings and revenue surprises of +191.67% and +13.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 29, 2026
Boost ROI via expanded gene panels, AI interpretation, tele-genetic counseling, routine prenatal integration and local reagent production to cut costs and widen access.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Pan-Ethnic Carrier Screening Programs Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global pan-ethnic carrier screening programs market is experiencing rapid growth as healthcare systems expand access to genetic testing across diverse populations. The
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTRA.
